This bill requires the Department of Defense to assess risks in its pharmaceutical supply chains, particularly regarding dependence on high-risk foreign suppliers. Within two years of enactment, the Defense Department must submit a report to Congress detailing what information it has about drug ingredients and manufacturing locations, especially those from countries deemed high-risk, and identify any obstacles to gathering or analyzing this supply chain data. The bill also directs the Defense Department to update its existing risk management guidance based on the findings in this report and to align its standards with Food and Drug Administration determinations about drug ingredients. No specific funding is allocated in the bill, but it aims to strengthen the Defense Department's ability to monitor vulnerabilities in the medications it purchases and uses for military personnel.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.